FDA WARNING_LETTER - Ultimark Products - April 19, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA issued a Warning Letter to Mr. Zuckerberg on April 13, 2022, concerning the distribution of PORCELANA DAY SKIN LIGHTENING CREAM. The product is cited as an unapproved new drug and a misbranded drug under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
The FDA determined PORCELANA DAY SKIN LIGHTENING CREAM is a drug intended for skin bleaching, based on claims on its label and website (Porcelana.com), such as "SKIN LIGHTENING CREAM," "FADES DARK SPOTS," and containing "Hydroquinone U.S.P. 2%." As a skin bleaching drug, it falls under section 505G(a)(4) of the FD&C Act, which deems such products not generally recognized as safe and effective (GRASE) per a 2006 proposed rule.
Consequently, the product is considered a new drug requiring an approved new drug application under section 505 of the FD&C Act, effective September 23, 2020. No such application exists for PORCELANA DAY SKIN LIGHTENING CREAM, violating section 505(a) and 301(d) of the FD&C Act. Furthermore, it is misbranded under section 502(ee) and 301(a) of the FD&C Act because it lacks an approved application and does
ID · c0cb7844-5d63-4868-b00c-2591ac8bd524
Full citation text and observation details available on the Dashboard.